A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients

Clinical trial NCT07185880 · RECRUITING

Trial details

NCT number: NCT07185880
Sponsor: Myosin Therapeutics Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Glioblastoma (GBM)

Start date: 2026-04-01
Primary completion: 2026-10-31
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.